Anagenics (ASX:AN1) - Outgoing CEO and Managing Director, Maria Halasz
Outgoing CEO and Managing Director, Maria Halasz
Source: Anagenics
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Anagenics (AN1) sees its board reshuffled following its transition to a digitally driven health and beauty tech company
  • Alexander (Sandy) Beard joins the board as Non-executive Chairman, effective from today
  • Meanwhile, Non-executive chairman of the company, Bruce Gordon, has submitted his resignation, following nearly 6 years with Anagenics
  • Following this, CEO and Managing Director of the company, Maria Halasz, has made the decision to transition out of her roles in the coming months
  • The exiting CEO has agreed to assist the board in the selection of her successor
  • Anagenics shares jumped 8 per cent, trading at 5.4 cents

Anagenics (AN1) has seen a reshuffle of its board following its transition to a digitally-driven health and beauty tech company.

Alexander (Sandy) Beard has joined the board as non-executive Chairman, effective from today.

Sandy comes from major shareholder Hancock and Gore where he is the Executive Chair, bringing with him significant experience in assisting the delivery of shareholder returns in small cap ASX-listed companies.   

Meanwhile, the Non-executive chairman of the company, Bruce Gordon, has submitted his resignation to the board.

Mr Gordon served on the Anagenics board since 2016, initially as Non-executive Director and Audit Committee Chairman, and from 2021 as Non-executive Chairman.

Following this, Maria Halasz, CEO and Managing Director of the company, has made the decision to transition out of her roles in the coming months. She has agreed to assist the board in the selection of a new CEO.

“On behalf of the Board I want to thank Maria for her dedicated service to the company,” said AN1 Chairman, Sandy Beard.

“I look forward to leading the Board of Anagenics through this next stage of growth and development.”  

Anagenics shares jumped 8 per cent, trading at 5.4 cents at the end of the trading day.

AN1 by the numbers
More From The Market Online

Week 17 Wrap: BHP-Anglo deal helps push down ASX; US data of concern but AI bulls happy

The big thematics and headlines that drove the ASX this week, plus, the headlines I think…
The Market Online Video

Market Close: ASX signs off on a sigh with all sectors red-lining

The ASX200 finished 1.3 per cent down with every sector in the red and Industrials and Real Estate brittle and bruised as bot…
The Market Online Video

Market Update: ASX on red alert with all sectors below the surface

The ASX200 is trading down around 1.1% with all eleven sectors in the red. Real-estate has…

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.